Entera Bio Ltd. (ENTX)
ENTX Stock Price Chart
Explore Entera Bio Ltd. interactive price chart. Choose custom timeframes to analyze ENTX price movements and trends.
ENTX Company Profile
Discover essential business fundamentals and corporate details for Entera Bio Ltd. (ENTX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
28 Jun 2018
Employees
22.00
Website
https://www.enterabio.comCEO
Miranda J. Toledano
Description
Entera Bio Ltd. is a biopharmaceutical firm in the clinical development phase, dedicated to creating and marketing oral medications composed of large molecules, addressing medical conditions that currently lack adequate treatments. Its primary experimental drugs are EB612, currently undergoing Phase II clinical assessment for hypoparathyroidism, and EB613, which has concluded Phase II studies for osteoporosis and is now in Phase I trials for treating non-healing bone fractures. Furthermore, the company holds a collaborative research and licensing pact with Amgen Inc. aimed at identifying and advancing potential therapeutic compounds for inflammatory conditions and other grave ailments. Established in 2009, Entera Bio Ltd. operates from its headquarters in Jerusalem, Israel.
ENTX Financial Timeline
Browse a chronological timeline of Entera Bio Ltd. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 14 Aug 2026
EPS estimate is -$0.08.
Earnings released on 8 May 2026
EPS came in at -$0.07 surpassing the estimated -$0.08 by +12.50%.
Earnings released on 27 Mar 2026
EPS came in at -$0.07 surpassing the estimated -$0.09 by +22.22%.
Earnings released on 14 Nov 2025
EPS came in at -$0.07 surpassing the estimated -$0.09 by +22.22%.
Earnings released on 8 Aug 2025
EPS came in at -$0.06 surpassing the estimated -$0.11 by +45.45%.
Earnings released on 9 May 2025
EPS came in at -$0.06 surpassing the estimated -$0.07 by +14.29%, while revenue for the quarter reached $42.00k .
Earnings released on 28 Mar 2025
EPS came in at -$0.06 surpassing the estimated -$0.08 by +25.00%, while revenue for the quarter reached $82.00k , beating expectations by +105.00%.
Earnings released on 8 Nov 2024
EPS came in at -$0.08 falling short of the estimated -$0.05 by -60.00%, while revenue for the quarter reached $42.00k , beating expectations by +5.00%.
Earnings released on 9 Aug 2024
EPS came in at -$0.06 matching the estimated -$0.06, while revenue for the quarter reached $57.00k .
Earnings released on 10 May 2024
EPS came in at -$0.05 surpassing the estimated -$0.06 by +16.67%.
Earnings released on 8 Mar 2024
EPS came in at -$0.07 surpassing the estimated -$0.08 by +12.50%, while revenue for the quarter reached $4.48m .
Earnings released on 14 Nov 2023
EPS came in at -$0.08 surpassing the estimated -$0.09 by +11.11%.
Earnings released on 11 Aug 2023
EPS came in at -$0.08 falling short of the estimated -$0.07 by -14.29%, while revenue for the quarter reached $14.00k .
Earnings released on 5 May 2023
EPS came in at -$0.08 surpassing the estimated -$0.12 by +33.33%, while revenue for the quarter reached $13.00k , missing expectations by -87.00%.
Earnings released on 27 Mar 2023
EPS came in at -$0.11 falling short of the estimated -$0.11 by -1.26%, while revenue for the quarter reached $14.00k , missing expectations by -72.00%.
Earnings released on 10 Nov 2022
EPS came in at -$0.11 surpassing the estimated -$0.16 by +31.25%, while revenue for the quarter reached $8.00k , missing expectations by -88.57%.
Earnings released on 11 Aug 2022
EPS came in at -$0.11 surpassing the estimated -$0.13 by +15.38%, while revenue for the quarter reached $44.00k , missing expectations by -56.00%.
Earnings released on 12 May 2022
EPS came in at -$0.13 surpassing the estimated -$0.16 by +18.75%, while revenue for the quarter reached $68.00k , missing expectations by -61.90%.
Earnings released on 8 Mar 2022
EPS came in at $0.21 surpassing the estimated -$0.11 by +290.91%, while revenue for the quarter reached $165.00k , beating expectations by +29.92%.
Earnings released on 10 Nov 2021
EPS came in at -$0.05 surpassing the estimated -$0.10 by +50.00%, while revenue for the quarter reached $140.00k , missing expectations by -25.93%.
Earnings released on 16 Aug 2021
EPS came in at -$0.19 falling short of the estimated -$0.10 by -90.00%, while revenue for the quarter reached $109.00k , beating expectations by +19.72%.
ENTX Stock Performance
Access detailed ENTX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
